Radioactive nanoparticles target cancer in the Brain's lining

NCT ID NCT07674693

Not yet recruiting Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests a radioactive drug called Rhenium-186 NanoLiposome (REYOBIQ) given directly into the brain's fluid space, combined with whole brain or proton radiation. It is for people with leptomeningeal metastases, where cancer has spread to the lining of the brain and spinal cord. The goal is to find a safe dosing schedule and see if it can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rhenium-186 NanoLiposome (REYOBIQ)
What this could lead to: If successful, this could provide a new treatment option for people with leptomeningeal metastases, a serious spread of cancer to the brain and spinal cord lining.
What could go wrong: This is an early Phase 1 trial with only 29 participants, so safety and effectiveness are not yet proven. The treatment involves radiation and a radioactive drug, which may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Meningeal Carcinomatosis neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEPTOMENINGEAL METASTASES

More trials for these conditions

Other studies related to the condition(s) this trial covers.